Hamill Laura — SEC insider filings
SEC reporting owner CIK 1751804. 22 insider filings on record with FilingPulse; latest filed 2026-09-02.
Transaction summary — filings shown
Covers all 22 filings on record, filed 2020-09-17 to 2026-09-02. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 41.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Y-mAbs Therapeutics, Inc. (YMAB) | Director | 6 | — | — | 16 |
| PARDES BIOSCIENCES, INC. (PRDS) | Director | 4 | — | — | 7 |
| ACCELERON PHARMA INC (XLRN) | Director | 3 | — | — | 6 |
| Jazz Pharmaceuticals plc (JAZZ) | Director | 4 | — | — | 6 |
| ANAPTYSBIO, INC (ANAB) | Director | 3 | — | — | 4 |
| FATE THERAPEUTICS INC (FATE) | Director | 1 | — | — | 1 |
| Scilex Holding Co (SCLX) | Director | 1 | — | — | 1 |
Insider filings — Hamill Laura
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-02 | 4 | Jazz Pharmaceuticals plc (JAZZ) | Tax withholding (F): 14 @ $244.06 · Tax withholding (F): 1,692 @ $241.39 | EDGAR |
| 2026-08-07 | 4 | Jazz Pharmaceuticals plc (JAZZ) | Grant/award (A): 1,605 @ $0 | EDGAR |
| 2026-06-15 | 4 | FATE THERAPEUTICS INC (FATE) | Grant/award (A): 175,800 (derivative) @ $0 | EDGAR |
| 2025-09-19 | 4 | Y-mAbs Therapeutics, Inc. (YMAB) | Code (U): 5,825 @ $8.60 · Disposition to issuer (D): 25,080 · Disposition to issuer (D): 27,000 (derivative) · Disposition to issuer (D): 11,000 (derivative) · Disposition to issuer (D): 16,000 (derivative) · Disposition to issuer (D): 13,950 (derivative) · +2 more | EDGAR |
| 2025-08-11 | 4 | Jazz Pharmaceuticals plc (JAZZ) | Grant/award (A): 3,507 @ $0 · Tax withholding (F): 1,805 @ $111.25 | EDGAR |
| 2025-07-02 | 4 | Y-mAbs Therapeutics, Inc. (YMAB) | Grant/award (A): 25,080 @ $0 · Grant/award (A): 33,450 (derivative) @ $0 | EDGAR |
| 2024-08-06 | 4 | Jazz Pharmaceuticals plc (JAZZ) | Grant/award (A): 3,731 @ $0 | EDGAR |
| 2024-06-13 | 4 | Y-mAbs Therapeutics, Inc. (YMAB) | Grant/award (A): 3,495 @ $0 · Grant/award (A): 14,545 (derivative) @ $0 | EDGAR |
| 2023-08-31 | 4 | PARDES BIOSCIENCES, INC. (PRDS) | Disposition to issuer (D): 37,500 (derivative) · Disposition to issuer (D): 70,390 (derivative) · Disposition to issuer (D): 75,000 (derivative) · Disposition to issuer (D): 37,500 (derivative) | EDGAR |
| 2023-06-09 | 4 | Y-mAbs Therapeutics, Inc. (YMAB) | Grant/award (A): 2,330 @ $0 · Grant/award (A): 13,950 (derivative) @ $0 | EDGAR |
| 2023-06-02 | 4 | PARDES BIOSCIENCES, INC. (PRDS) | Grant/award (A): 37,500 (derivative) @ $0 | EDGAR |
| 2023-01-17 | 4 | Scilex Holding Co (SCLX) | Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2023-01-10 | 4 | ANAPTYSBIO, INC (ANAB) | Grant/award (A): 10,600 (derivative) @ $0 · Grant/award (A): 3,900 (derivative) @ $0 | EDGAR |
| 2022-07-19 | 4 | Y-mAbs Therapeutics, Inc. (YMAB) | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | PARDES BIOSCIENCES, INC. (PRDS) | Grant/award (A): 37,500 (derivative) @ $0 | EDGAR |
| 2022-02-14 | 4 | ANAPTYSBIO, INC (ANAB) | Grant/award (A): 9,200 (derivative) @ $0 | EDGAR |
| 2021-12-28 | 4 | PARDES BIOSCIENCES, INC. (PRDS) | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2021-11-22 | 4 | ACCELERON PHARMA INC (XLRN) | Code (U): 474 · Disposition to issuer (D): 9,339 (derivative) · Disposition to issuer (D): 941 (derivative) | EDGAR |
| 2021-06-14 | 4 | Y-mAbs Therapeutics, Inc. (YMAB) | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2021-02-12 | 4 | ANAPTYSBIO, INC (ANAB) | Grant/award (A): 11,000 (derivative) @ $0 | EDGAR |
| 2021-02-02 | 4 | ACCELERON PHARMA INC (XLRN) | Grant/award (A): 474 @ $0 · Grant/award (A): 941 (derivative) @ $0 | EDGAR |
| 2020-09-17 | 4 | ACCELERON PHARMA INC (XLRN) | Grant/award (A): 9,339 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-09-16 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1751804 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs